# A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases

> **NCT07412691** · PHASE1 · RECRUITING · sponsor: **BeOne Medicines** · enrollment: 98 (estimated)

## Conditions studied

- Skin Diseases

## Interventions

- **BIOLOGICAL:** BG-A3004
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07412691
- **Lead sponsor:** BeOne Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-19
- **Primary completion:** 2028-08-08
- **Final completion:** 2028-08-08
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07412691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07412691, "A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT07412691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*